3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Prostatic Neoplasms
34
Prostatic Neoplasms, Castration-Resistant
3
Metastatic Castration-resistant Prostate Cancer
2
Metastatic Castration-Resistant Prostate Cancer
2
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Prostate Cancer Metastatic Disease
1
Prostate Adenocarcinoma
1
Newly Diagnosed Oligometastatic Prostate Cancer
1
Neoadjuvant Therapy
1
Metastatic Hormone-sensitive Prostate Cancer
1
Melanoma
1
Disease
1
Castration-resistant Prostate Cancer
1
Castrate Sensitive Prostate Cancer
1
Carcinoma, Small Cell
1
Carcinoma, Non-Small-Cell Lung
1
Anus Neoplasms
1
Interventions
Fluorouracil
13
Cisplatin
7
Radiotherapy
6
Specimen Handling
5
Mitomycin
5
Capecitabine
5
pembrolizumab
4
dehydroftorafur
4
Radiation
4
Drug Therapy
4
Cetuximab
4
Radiotherapy, Intensity-Modulated
3
Paclitaxel
3
Nivolumab
3
Magnetic Resonance Spectroscopy
3
Carboplatin
3
Biopsy
3
tislelizumab
2
durvalumab
2
aldesleukin
2
VGX-3100
2
Platinum
2
Mitozytrex
2
Immune Checkpoint Inhibitors
2
Fluorodeoxyglucose F18
2
1,2-diaminocyclohexaneplatinum II citrate
2
toripalimab
1
technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran
1
spartalizumab
1
rocakinogene sifuplasmid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Anus Neoplasms
×
abiraterone
×
Clear all
NCT05551117
2026-02-09
Tamarack
MacroGenics
Phase 2
Terminated
192 enrolled
20 charts